Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled reviewed curcumin as a possible ALS treatment

Original source

CurcuminALSUntangled · 1 March 2018 (opens in a new tab)

ALS Untangled reviewed the available evidence on oral curcumin for people with ALS (PALS). The review described theoretical mechanisms, flawed preclinical findings, improvements in three people receiving regimens that included curcumin, and a small pilot trial reporting some benefit. The reviewers said some of them planned a trial of Theracurmin, a curcumin formulation, at 90 mg twice daily.

Why this matters

Curcumin is being considered for further study, but this review does not establish that it treats ALS. The reported improvements have alternative possible explanations, and the preclinical and clinical evidence described is limited. A planned trial would be needed to test the treatment more rigorously.

Limitations and context

This is an expert review, not a new primary research study. The review describes flawed preclinical studies, three individual cases with possible alternative explanations, and one small pilot trial. It reports that a trial was planned, not that the trial had been completed or had produced results.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?